LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

After hours: March 14 at 7:35:32 PM EDT ...

DAWN Day One Biopharmaceuticals, Inc.

Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports.

Capital, LLC EcoR1, a director at $ZYME, bought 468,356 shares of the company on 03-13-2025 for an estimated $5,847,237. This trade was reported by Quiver ...

Insiders are still scooping up shares of stocks, including huge buys at two energy companies, an apparel retailer, and a ...